Pellish R S, Nasir A, Ramratnam B, Moss S F
Division of Gastroenterology, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI 02903, USA.
Aliment Pharmacol Ther. 2008 May;27(9):715-23. doi: 10.1111/j.1365-2036.2008.03634.x. Epub 2008 Feb 1.
A new technique of gene regulation, termed RNA interference, has emerged recently. RNA interference utilizes short double-stranded RNA to inhibit selectively gene expression of complementary RNA nucleotide sequences after transcription, but prior to translation. Gastrointestinal and hepatic disorders may be particularly amenable to therapeutic RNA interference intervention because of the relative ease of delivery of drugs to the gastrointestinal tract and liver.
To examine the published literature for potential clinical uses of RNA interference in gastroenterology and speculate on future therapies for luminal disease.
Reports were identified using PubMed and the search term 'RNA interference', focusing on therapeutic uses related to gastrointestinal and liver disease.
Cellular and animal models demonstrate the potential application of short-interfering RNA-based therapies for viral hepatitis and inflammatory bowel disease. With validation of specific targets and better in vivo delivery of short-interfering RNA, RNA interference may represent a new frontier for molecular-targeted therapy in gastroenterology and hepatology.
Short-interfering RNA provides a novel and specific means to inhibit gene expression. Translation to the clinical arena will require further definition of side-effects, off-target effects and delivery systems. Ultimately, mucosally applied or endoscopically delivered short-interfering RNA could be one of the earliest clinical uses of short-interfering RNA therapy.
一种名为RNA干扰的基因调控新技术最近出现。RNA干扰利用短双链RNA在转录后但翻译前选择性抑制互补RNA核苷酸序列的基因表达。由于药物相对容易递送至胃肠道和肝脏,胃肠道和肝脏疾病可能特别适合接受治疗性RNA干扰干预。
查阅已发表的文献,了解RNA干扰在胃肠病学中的潜在临床应用,并推测腔内疾病的未来治疗方法。
使用PubMed和检索词“RNA干扰”来识别相关报告,重点关注与胃肠和肝脏疾病相关的治疗用途。
细胞和动物模型证明了基于短干扰RNA的疗法在病毒性肝炎和炎症性肠病中的潜在应用。随着特定靶点的验证以及短干扰RNA在体内递送的改善,RNA干扰可能代表胃肠病学和肝病学中分子靶向治疗的一个新前沿。
短干扰RNA提供了一种抑制基因表达的新颖且特异的方法。向临床领域的转化将需要进一步明确副作用、脱靶效应和递送系统。最终,黏膜应用或内镜递送的短干扰RNA可能是短干扰RNA疗法最早的临床应用之一。